Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Datascope brings Anestar production to US:

This article was originally published in Clinica

Executive Summary

Datascope is shifting production of its Anestar and Anestar S anaesthesia delivery systems from Germany to its facility in New Jersey, having bought the manufacturing rights to the devices from its OEM partner. The move will enable the company to enhance its line of anaesthesia systems without the restrictions of an OEM agreement as well as giving it a competitive boost in the anaesthesia delivery and OR (operating room) patient monitor markets. Datascope, of Montvale, New Jersey, estimates that these two markets together generate $700m in annual worldwide sales.

You may also be interested in...



Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.

US FDA Requests Frequent Updates On Supply Chain Disruptions In COVID-19 Era

Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.

Topics

UsernamePublicRestriction

Register

MT060404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel